Equillium Net Worth
Equillium Net Worth Breakdown | EQ |
Equillium Net Worth Analysis
Equillium's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Equillium's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Equillium's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Equillium's net worth analysis. One common approach is to calculate Equillium's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Equillium's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Equillium's net worth. This approach calculates the present value of Equillium's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Equillium's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Equillium's net worth. This involves comparing Equillium's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Equillium's net worth relative to its peers.
Enterprise Value |
|
To determine if Equillium is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Equillium's net worth research are outlined below:
| Equillium generated a negative expected return over the last 90 days | |
| Equillium has high historical volatility and very poor performance | |
| Equillium has some characteristics of a very speculative penny stock | |
| The company generated the yearly revenue of 36.08 M. Annual Net Loss to common stockholders was (13.34 M) with gross profit of 15.76 M. | |
| Equillium reports about 57.56 M in cash with (21.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Equillium has a very weak financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company shares are held by company insiders | |
| Latest headline from forbes.com: AI IQ And EQ Or The Message And The Messenger |
Equillium uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Equillium. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Equillium's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Equillium's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Equillium is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Equillium backward and forwards among themselves. Equillium's institutional investor refers to the entity that pools money to purchase Equillium's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Integrated Wealth Concepts Llc | 2024-03-31 | 40 K | Northern Trust Corp | 2024-03-31 | 35 K | Prudential Financial Inc | 2024-03-31 | 31.2 K | Commonwealth Equity Services Inc | 2024-03-31 | 25 K | Springbok Capital Management, Llc | 2024-03-31 | 15.5 K | Susquehanna International Group, Llp | 2024-03-31 | 14.7 K | Jane Street Group, Llc | 2023-12-31 | 12 K | Marshall Wace Asset Management Ltd | 2024-03-31 | 11.9 K | Ground Swell Capital, Llc | 2024-03-31 | 11.4 K | Decheng Capital Llc | 2024-03-31 | 4.4 M | Vanguard Group Inc | 2024-03-31 | 841.9 K |
Follow Equillium's market capitalization trends
The company currently falls under 'Micro-Cap' category with a market capitalization of 28.2 M.Market Cap |
|
Project Equillium's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.63) | (0.66) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | (0.59) | (0.62) |
When accessing Equillium's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Equillium's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Equillium's profitability and make more informed investment decisions.
The data published in Equillium's official financial statements typically reflect Equillium's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Equillium's quantitative information. For example, before you start analyzing numbers published by Equillium accountants, it's essential to understand Equillium's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Equillium's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Equillium. Check Equillium's Beneish M Score to see the likelihood of Equillium's management manipulating its earnings.
Evaluate Equillium's management efficiency
Equillium has Return on Asset (ROA) of (0.1431) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1431. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.4817) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/27/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 07/27/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.65 | 0.62 | |
| Tangible Book Value Per Share | 0.65 | 0.62 | |
| Enterprise Value Over EBITDA | (0.19) | (0.20) | |
| Price Book Value Ratio | 1.11 | 1.53 | |
| Enterprise Value Multiple | (0.19) | (0.20) | |
| Price Fair Value | 1.11 | 1.53 | |
| Enterprise Value | 2.7 M | 2.6 M |
The analysis of Equillium's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Equillium's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Equillium Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 0.7369 | Revenue 37.9 M | Quarterly Revenue Growth 0.204 | Revenue Per Share 1.085 | Return On Equity (0.48) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Equillium insiders, such as employees or executives, is commonly permitted as long as it does not rely on Equillium's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Equillium insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Troupin Barbara over two months ago Acquisition by Troupin Barbara of 20000 shares of Equillium at 1.43 subject to Rule 16b-3 | ||
Troupin Barbara over two months ago Insider Trading | ||
Stephen Connelly over three months ago Disposition of 8490 shares by Stephen Connelly of Equillium at 7.0842 subject to Rule 16b-3 | ||
Zedelmayer Christine over three months ago Acquisition by Zedelmayer Christine of 8334 shares of Equillium at 2.45 subject to Rule 16b-3 | ||
Joel Rothman over three months ago Acquisition by Joel Rothman of 8804 shares of Equillium subject to Rule 16b-3 | ||
Jason Keyes over six months ago Acquisition by Jason Keyes of 15000 shares of Equillium subject to Rule 16b-3 | ||
Charles McDermott over a year ago Acquisition by Charles McDermott of 24000 shares of Equillium subject to Rule 16b-3 |
Equillium Earnings per Share Projection vs Actual
Equillium Corporate Management
| Jason Keyes | Chief Officer | Profile | |
| Matthew Ritter | Senior Development | Profile | |
| Penny Tom | Principal Officer | Profile | |
| Maple MD | Chief Officer | Profile | |
| Krishna MD | Consultant | Profile |
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.